AIM2 and cancer: Activation of the AIM2 inflammasome in macrophages and the subsequent production of IL‐1β contribute significantly to cytokine release syndrome in cancer patients undergoing CAR‐T therapy, and limiting the AIM2 pathway potentially mitigates adverse survival outcomes following CAR‐T treatment, thus implicating a connection between AIM2 and the promotion of pro‐inflammatory macrophage polarization.32